Equibles does not estimate personal net worth.
Get an email with a short summary when Iovance Biotherapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get IOVA alertsSara Pellegrino has spoken on 15 earnings calls and 1 other investor event across 1 company, most recently for Iovance Biotherapeutics, Inc. on September 15, 2026. Iovance Biotherapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Iovance Biotherapeutics, Inc. includes Frederick G. Vogt, Ph.D. (CEO), Frederick Vogt (CEO and General Counsel), Corleen Roche (CFO) and 7 others.
“Good morning and welcome to the Iovance webcast to discuss our fourth quarter and full year 2025 financial results, business achievements, and corporate updates.”
“Good morning and welcome to the Iovance webcast to discuss our second quarter 2026 financial results, business achievements, and corporate updates.”
“Good morning, and welcome to the Iovance webcast to discuss our first quarter 2026 financial results, business achievements, and corporate updates.”
“Good morning and welcome to the Iovance webcast to discuss our fourth quarter and full year 2025 financial results, business achievements, and corporate updates.”
“Good morning, and welcome to the Iovance webcast to discuss our business achievements, pipeline milestones, and third quarter 2025 results.”
Source not stated
Biotechnology · Healthcare
